Fazio Francesca, Franceschini Luca, Tomarchio Valeria, Rago Angela, Garzia Maria Grazia, Cupelli Luca, Bongarzoni Velia, Andriani Alessandro, Gumenyuk Svitlana, Tafuri Agostino, Siniscalchi Agostina, Piciocchi Alfonso, De Fabritiis Paolo, De Rosa Luca, Caravita di Toritto Tommaso, Annibali Ombretta, Cantonetti Maria, Petrucci Maria Teresa
Department of Translational and Precision Medicine, Hematology Azienda Policlinico Umberto I Sapienza University of RomeSapienza Università di Roma.
Transplant Network, Hematology-Stem Cell Transplant Unit Rome Italy.
EJHaem. 2022 Jan 15;3(1):121-128. doi: 10.1002/jha2.359. eCollection 2022 Feb.
The multiple myeloma (MM) treatment has changed over the last years due to the introduction of novel drugs. Despite improvements in the MM outcome, MM remains an incurable disease. Daratumumab is a human IgGK monoclonal antibody targeting CD38 with tumor activity associated with immunomodulatory mechanism. In combination with standard of care regimens, including bortezomib (Vd) or lenalidomide (Rd), daratumumab prolonged progression-free survival (PFS) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) and in new diagnosis MM. We report the data of the MM GIMEMA Lazio group in 171 heavily treated pts who received daratumumab, lenalidomide and dexamethasone (DRd) or daratumumab, velcade and dexamethasone (DVd). The overall response rate was 80%, and the overall survival (OS) and PFS were 84% and 77%, respectively. In addition, pts treated with DRd showed a better median PFS compared to pts treated with DVd, at 12 and 24 months, respectively. The most common hematologic treatment-emergent adverse events (TAEs) were neutropenia, thrombocytopenia, and anemia. The most common nonhematologic TAEs were peripheral sensory neuropathy and infections. Our data confirmed that DRd or DVd therapy is effective and safe in RRMM pts, and our real-life analysis could support the physicians regarding the choice of optimal therapy in this setting of pts.
在过去几年中，由于新型药物的引入，多发性骨髓瘤（MM）的治疗发生了变化。尽管MM的治疗效果有所改善，但MM仍然是一种无法治愈的疾病。达雷妥尤单抗是一种靶向CD38的人IgGK单克隆抗体，其肿瘤活性与免疫调节机制相关。与包括硼替佐米（Vd）或来那度胺（Rd）在内的标准治疗方案联合使用时，达雷妥尤单抗可延长复发/难治性多发性骨髓瘤（RRMM）患者和新诊断MM患者的无进展生存期（PFS）。我们报告了MM GIMEMA拉齐奥组171例接受达雷妥尤单抗、来那度胺和地塞米松（DRd）或达雷妥尤单抗、万珂和地塞米松（DVd）治疗的重度治疗患者的数据。总缓解率为80%，总生存期（OS）和PFS分别为84%和77%。此外，接受DRd治疗的患者在12个月和24个月时的中位PFS分别比接受DVd治疗的患者更好。最常见的血液学治疗中出现的不良事件（TAEs）是中性粒细胞减少、血小板减少和贫血。最常见的非血液学TAEs是周围感觉神经病变和感染。我们的数据证实，DRd或DVd治疗在RRMM患者中是有效且安全的，我们的真实世界分析可为医生在这类患者中选择最佳治疗方案提供支持。
